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1. Introduction 
Liver fibrosis is the final pathway for most chronic liver disease and is the main reason for 
increased mortality in affected patients. The extent of liver fibrosis displays great individual 
variation, even after controlling for age (at infection), gender & exogenous factors. Thus, 
host genetic factors are likely to play an important role in the process of liver scarring. 
(Weber et al., 2008).  Inflammation is strongly associated with chronic liver injury, and 
fibrosis is part of the liver’s wound-healing response. Inflammation represents the driving 
force for the progressive accumulation of extracellular matrix (ECM) components, 
eventually leading to liver cirrhosis and hepatic failure. Although even acute injury will 
activate mechanisms of fibrogenesis, the sustained signals of inflammation associated with 
chronic liver disease caused by infection, drugs, metabolic disorders, or immune attacks are 
required for significant fibrosis to accumulate. Cirrhosis is the result of many liver diseases 
and consists of fibrosis and regenerating nodules. Clinical presentations vary from 
asymptomatic to advanced end stage liver diseases with complications. In addition, a 
significant need exists for developing safe and accurate noninvasive technique for detecting 
progression or regression of hepatic fibrosis in patients with chronic liver disease 
(Fallowfield JA et al., 2006).  
The past few years have seen remarkable progress in the field of liver fibrosis, including 
understanding the crosstalk between innate immunity and inflammatory cells & pathways 
regulating fibrosis regression. This article will review recent advances in this field as well as 
imaging and diagnostic test of liver fibrosis. 
2. Advances in the mechanisms of fibrogenesis 
Liver fibrogenesis is characterized by cellular activation of hepatic stellate cells (HSCs) and 
its mediators. HSCs have dominated studies exploring mechanisms of liver fibrosis over the 
last two decades. HSCs are resident vitamin A-storing cells in the perisinusoidal space of 
Disse between the sinusoidal endothelium and hepatocytes. Following hepatic injury, HSCs 
become activated into a myofibroblast-like phenotype that is contractile, proliferative and 
fibrogenic.  Collagen and other ECM components are deposited which result in a fibrous 
scar eventually leading to cirrhosis and liver failure (Lee & Friedman, 2011).  Liver fibrosis is 
a dynamic process, resulting from the equilibrium between fibrogenesis and altered matrix 
degradation, and may be reversible prior to the establishment of advanced architectural 
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changes to the liver. HSC represent the final common pathway of the wound-healing 
response of the liver. Activation consists of two major phases, initiation (also called a 
‘preinflammatory stage’) and perpetuation, followed by a resolution phase if the injury 
subsides (Friedman, 1993).  Following alcohol consumption, cholestasis and iron overload, 
reactive oxygen species (ROS) and lipid peroxidation products are generated in large 
amounts leading to Kupffer cell activation. Activated Kupffer cells, infiltrating circulating 
monocytes, activated and aggregated platelets, and damaged hepatocytes are sources of 
platelet-derived growth factor (PDGF) and transforming growth factor-b1 (TGF-b1), which 
both trigger the initiation of intracellular signaling cascades after binding to HSC surface 
receptors. Activated HSC lose vitamin A droplets and increase expression of cytoskeletous 
proteins such as desmin and ǂ-smooth muscle actin, which are associated with augmented 
contractile activity, as well as generate ECM, which includes type I and III collagen 
(Kawada, 2011). In addition, augmented production of the tissue inhibitor of matrix 
metalloproteinases (TIMP) hampers the degradation of ECM and conversely stimulates their 
accumulation in the inflamed liver. Activated HSC, also known as myofibroblasts (MFB), 
are contractile and their capacity to generate contractile force mediates the liver’s injury 
response through modulation of sinusoidal blood flow and scar contracture.  
Metalloproteinases-1 (MMP-1) is a key collagenase that metabolizes type I collagen; 
however, MMP activity also strictly regulates its binding partner, TIMP. Because HSC are 
able to generate both TIMP-1 and -2, a local balance between MMP and TIMP plays an 
important role in fostering the resolution of the fibrotic process (Benyon & Arthur, 2001). 
The liver’s response to injury is an angiogenic one, with evidence of new blood vessel 
formation, sinusoidal remodeling, and HSC expansion (Lee et al., 2007).  Neo-angiogenesis 
is stimulated in hepatic tissue by the progressive increase of tissue hypoxia. PDGF, vascular 
endothelial growth factor (VEGF), and their receptors as well as vasoactive mediators 
including nitric oxide and carbon monoxide are upregulated during liver fibrosis. This 
mechanism is strictly linked to the anatomical alterations following the establishment of 
periportal fibrosis with an increased contribution of the hepatic artery to the formation of 
sinusoidal blood. Accordingly, sinusoidal blood flow becomes increasingly arterialized with 
hepatocytes adjusting to an abnormally high oxygen concentration. Subsequently, the 
progressive capillarization of sinusoids leads to an impairment of oxygen diffusion from the 
sinusoids to hepatocytes with the consequent up-regulation of pro-angiogenic pathways 
(Pinzani et al., 2011). For example, increased VEGF concentrations may contribute to the 
accelerated progression of fibrosis in smokers who have hepatitis C (Dev et al., 2006). 
The excess deposition of ECM proteins disrupts the normal architecture of the liver, which 
alters the normal function of the organ, ultimately leading to portal hypertension (PH) 
which is the earliest and most important consequence of cirrhosis and underlies most of the 
clinical complications of the disease. PH results from an increased intrahepatic resistance 
combined with increased portal (and hepatic arterial) blood flow.  
Leptin, a key adipokine, has been implicated in fibrogenesis through a number of pathways. 
Leptin, a circulating adipogenic hormone, promotes stellate cell fibrogenesis and enhances 
TIMP-1 expression, which is associated with increased leptin signaling (Leclercq et al., 2002). 
Recent investigations have revealed the participation of mesenchymal cells, which originate 
from bone marrow, in liver fibrosis by using rodent models and damaged human livers 
(Forbes et al., 2004; Kisseleva et al., 2006).  Similarly, fibrocytes in circulation and portal 
fibroblasts are acknowledged as fibrotic players (Dranoff  & Wells, 2010).  Furthermore, an 
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epithelial–mesenchymal transition (EMT) may be involved in the fibrotic process in the liver 
as well as in the kidney and lung (Zeisberg et al., 2007).  
Perpetuation of the hepatic fibrotic process is supported by the activation of HSC and the 
presence of MFB, which are continuously stimulated by growth factors, cytokines and 
oxidative stress derived from nearby cells. Damaged hepatocytes are a source of lipid 
peroxides and ROS generated from hepatocytic mitochondria (Jiang et al., 2010).  
Macrophage chemotactic protein-1 (MCP-1) and osteopontin derived from activated Kupffer 
cells are involved in the infiltration of inflammatory cells into the liver (Syn et al., 2011). 
Liver fibrosis is the final common pathway of the wound-healing response of the liver 
which can progress to liver fibrosis and eventually cirrhosis. At the cellular and molecular 
level, this progressive process is characterized by cellular activation of HSCs and aberrant 
activity of TGF-ǃ with its downstream cellular mediators.  
3. Reversibility of liver fibrosis and cirrhosis 
Regression of fibrosis and cirrhosis in humans is not a novel concept. Anecdotal reports 
published more than forty years ago recorded an improvement in patients with cirrhosis 
treated for hemochromatosis and Wilson disease (Powell & Ker, 1970; Falkmer et al., 1970).   
Advanced fibrosis and cirrhosis has recently been described with respect to matrix turnover 
in trials of antiviral therapy for chronic viral hepatitis (Poynard et al., 2002).  The issue of 
regression/reversibility of cirrhosis originates from evidence obtained in animal models 
upon the discontinuation of the cause of liver damage or following treatment with 
antifibrotic agent. In chronic liver injury, activated HSC are major source of fibrillar ECM as 
well as of the TIMPs which inhibit collagen degradation (Bataller & Brenner, 2005).  HSC 
survival and apoptosis are regulated by growth factors expressed during fibrotic liver 
injury. Thus,HSC apoptosis plays a critical role in the recovery from biliary as well as toxic-
induced liver fibrosis (Iredale et al., 1998).  Moreover, the very striking improvement in the 
histological appearance in these reports suggests that the number of activated HSCs is 
reduced as well. By definition, the resolution of an injury with a return to normal histology 
must involve the loss or phenotypic reversal to quiescence of activated HSCs (Iredale, 2001).  
On the other hand, activated HSC produce the fibrolytic MMPs resulting in extracellular 
degradation and scar remodelling. Similarly, kuffer cells/macrophages appear instrumental 
in the reversal of established fibrosis when the fibrogenic stimulus is absent; while they can 
fuel fibrogenesis when the trigger is present (Duffield et al., 2005).   Clearly, at some point 
(probably coinciding with the onset of the clinical symptoms of cirrhosis), fibrosis becomes 
irreversible. Animal models suggest that this event coincides with a significant collagen 
cross-linking by tissue transglutaminase, leading to the production of an insoluble matrix 
(Issa et al., 2004).  
These observations have enhanced our understanding of the pathogenesis of liver fibrosis 
and defined our approach to its treatment. When hepatocyte necrosis occurs, the remaining 
hepatocytes undergo proliferation, leading to repair of the local environment. These 
processes are stimulated by growth factors derived from HSC, such as HGF, epidermal 
growth factor, epimorphin and pleiotrophin (Sawitza et al., 2009).  It is difficult to say when 
cirrhosis becomes irreversible. Fibrotic deposition related to recent disease and 
characterized by the presence of thin reticulin fibers, often in the presence of a diffuse 
inflammatory infiltrate, is likely fully reversible. However, longstanding fibrosis, branded 
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by extensive collagen cross-linking, dense acellular/paucicellular ECM and decreased 
expression and/or activity of specific metalloproteinases, is likely irreversible (Issa et al., 
2004; Pinzani & Rombouts, 2004). For example, cirrhosis following withdrawal of an 
injurious stimulus can undergo remodeling of dense micronodular cirrhosis to a more 
attenuated, macronodular pattern. However, some septa will persist, likely representing 
those laid down early in the injury, and are therefore the most “mature” (i.e., cross-linked) 
(Friedman, 2003).    
Evidence of fibrotic regression has now been documented in chronic liver diseases, 
including autoimmune hepatitis, biliary obstruction, iron overload, Non-alcoholic 
steatohepatitis, and viral hepatitis B and C (Ismail & Pinzani, 2009). Poynard et al., 2002 
examined liver biopsy specimens taken before and after therapy from 153 patients with 
HCV-related cirrhosis treated with different pegylated interferon and ribavirin regimens. 
Using the METAVIR scoring system, they found that the extent of liver fibrosis had 
improved in 75 (49%) Stage-4 patients: to Stage 3 in 23 patients, to Stage 2 in 26 patients, to 
Stage 1 in 23 patients, and to a virtually normal histological appearance in three patients. No 
such improvements were recorded in the control group of patients treated with interferon 
monotherapy. Reversal of cirrhosis was more common among younger patients. 
4. Evaluation of liver fibrosis 
The accurate and early diagnosis of liver fibrosis is crucial for long-term prognosis (Castera 
& Pinzani, 2010).  The complete evaluation of a patient with diffuse liver diseases requires 
clinical evaluation, laboratory tests and pathological examination. Standard liver tests (ALT, 
AST, Bilirubin…etc) are of limited value in assessing the degree of fibrosis. Currently, 
histological examination of a liver biopsy specimen is the reference standard for the 
diagnosis, staging, and monitoring of liver fibrosis (Bravo et al., 2001; Campbell & Reddy, 
2004). Three staging systems are commonly used to classify liver fibrosis: the Knodell, 
METAVIR and Ishak scores (Knodell et al., 1981; Desmet et al., 1994; Anthony et al., 1978). 
Knodell and METAVIR score fibrosis from Stages 0 to 4, with Stage 4 as cirrhosis, whereas 
Ishak scores fibrosis from Stages 0 to 6, with 5 as incomplete or early cirrhosis and 6 as 
established cirrhosis. There are several situations in which the role of liver biopsy (LB) is 
being challenged. These methods are semi-quantitative which make it a poor choice when 
considering assessment of liver fibrosis progression or regression. Furthermore, there is the 
issue of sampling error, defined as variable levels of fibrosis throughout the liver, with 
biopsy only examining a small portion of the liver (around 1/50000th of liver mass is 
obtained) (Bedossa et al., 2003). In addition, histological examination is prone to 
intraobserver and interobserver variation, which may occur even when widely validated 
systems are used to assess liver damage (Regev et al., 2002).  Finally, liver biopsy is an 
invasive procedure with associated morbidity: pain occurs in 20% of patients and major 
complications (such as bleeding or hemobilia) in 0.5% of patients (Huang et al., 2007; Rockey 
et al., 2009). 
5. Noninvasive markers of fibrosis 
Over the past years, several non-invasive tests have become available for clinicians to use to 
assess liver fibrosis and determine the best course of management for their patients, 
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especially those with chronic hepatitis C (Afdhal, 2003; Kotlyar et al., 2008).  Initial studies of 
noninvasive markers largely consisted of single components, but the field has evolved into 
combining these single components into panel markers. Several laboratory tests, scores, and 
indices have been proposed for noninvasive prediction of hepatic fibrosis in patients with 
chronic hepatitis C. Among these is the aspartate aminotransferase (AST)/alanine 
aminotransferase (ALT) ratio (AAR) (Saadeh et al., 2001; Giannini et al., 2003; Williams & 
Hoofnagle, 1988).  A ratio >1 has been proposed as a test for cirrhosis. However, the test is 
disadvantaged by both poor sensitivity (53.2%) and a negative predictive value (80.7%). 
Forns fibrosis index (FFI) (Forns, 2002) was developed as a model to predict fibrosis in 
patients with HCV based on age, gamma glutamyl transferase (gGT), cholesterol and 
platelet count. The score derived from this was validated against liver histology using the 
METAVIR scoring system for hepatic fibrosis, and it was found to have a sensitivity of 94% 
& specificity of 51% for a cut-off value of >4.2 (for absence of fibrosis) and a sensitivity of 
30% & specificity of 95% for a cut-off value of > 6.9 (for presence of fibrosis). Low platelet 
count per se (Ono et al., 1999) can predict advanced fibrosis. The AST-to-platelet ratio index 
(APRI) (Wai et al., 2003) is formulated by dividing the AST by the upper limit of normal AST 
divided by the platelet count and multiplied by 100. In the initial study in patients with 
HCV, the APRI was derived from a training set of 192 patients undergoing liver biopsy. The 
area under the curve (AUC) for predicting significant fibrosis (Ishak fibrosis score ≥ 3) and 
cirrhosis were 0.82 and 0.92, respectively, in the training set, and 0.80 and 0.89, respectively, 
in the validation set for 78 patients. Using optimized cut-off values, this test predicted 
significant fibrosis in 51% and cirrhosis in 81% of patients. Other similar scoring systems 
that have been applied include the cirrhosis discriminant score (Bonacini et al., 1997), age–
platelet index (Poynard et al., 1997) and Pohl score (Pohl et al., 2007).  These tests were 
compared in a study comparing AAR, CDS, AP index, Pohl score and APRI (Lackner et al., 
2005). In this study of 194 patients, AUC analysis revealed similar diagnostic accuracy for 
CDS, AP index, APRI and platelet count for the prediction of significant fibrosis (Ishak score 
≥3) (AUCs of 0.71, 0.74, 0.80 and 0.71, respectively) and cirrhosis (AUCs of 0.91, 0.91, 0.90 
and 0.89, respectively). FIB-4 (Vallet-Pichard et al., 2007) is a recently described marker of 
fibrosis derived from a formula utilizing AST, ALT, age and platelets. In a series of 847 
biopsies from HCV monoinfected patients comparing FIB-4 values to liver biopsy and 
FibroTest values, FIB-4 values <1.45 or >3.25 (64.6% cases) were concordant with FibroTest 
results in 92.1% and 76% of cases, respectively. Using the METAVIR scoring system to 
record fibrosis, this test had an AUC of 0.85 (95% CI 0.82–0.89) for prediction of severe 
fibrosis (F3–4) and 0.91 (95% CI 0.86–0.93) for prediction of cirrhosis. The FibroIndex was 
derived from an estimation set of 240 patients and validated in 120 subsequent patients. The 
test was derived from platelet count, AST and gamma globulin. Using this method, the AUC 
for the detection of significant fibrosis using the METAVIR histological classification of 
fibrosis (≥F2) was 0.83 in the estimation set and 0.82 in the validation set. Although it was 
calculated using best cut-offs for PPV, only 35% of patients avoided LB. 
FibroTest-ActiTest (FT-AT), from BioPredictive, Paris, France, is a noninvasive blood test 
that combines the quantitative results of six serum biochemical markers [alfa2-
macroglobulin, haptoglobin, gamma glutamyl transpeptidase, total bilirubin, apolipoprotein 
A1 and ALT] with patients’ age and gender in a patented algorithm to generate a measure of 
fibrosis and necroinflammatory activity in the liver (Imbert-Bismut et al., 2001; Poynard et 
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Abbreviations used: GGT: g-glutamyl-transpeptidase; AST: aspartate transaminase; chronic hepatitis C: 
HCV; Se: sensitivity; Sp: specificity; AUC: area under the receiver operator characteristic curve; t: 
Training group; v: Validation group. An AUC of 1.0 is characteristic of an ideal test, where as an AUC 
of 0.5 or less indicates a test of no diagnostic value. 
Table 1. Diagnostic performance of common non-invasive tests of liver fibrosis. 
B
io
m
a
rk
e
r 
(R
e
f.
) 
P
a
ra
m
e
te
rs
 
P
a
ti
e
n
ts
 
F
2
-3
-4
 
(%
) 
A
U
C
 
S
e
 
(%
) 
S
p
 
(%
) 
P
P
V
/N
P
V
 
(%
) 
F
o
rn
s 
F
ib
ro
si
s 
In
d
e
x
  2
00
2 
(K
o
tl
y
ar
 e
t 
al
., 
20
08
) 
A
g
e,
 p
la
te
le
t 
co
u
n
t,
 
G
G
T
P
 a
n
d
 c
h
o
le
st
er
o
l.
 
H
C
V
 
26
%
 
t 
=
0.
86
, v
 =
0.
81
 
91
 
51
 
66
/
96
 
A
P
R
I 
In
d
e
x
 2
00
3 
(G
ia
n
n
in
i 
et
 a
l.
, 2
00
3)
 
A
S
T
/
P
la
te
le
t 
R
at
io
 
H
C
V
 
50
 
t 
=
0.
80
, v
 =
0.
90
 
89
 
75
 
91
/
90
 
F
ib
ro
te
st
 2
00
1 
 
(P
o
y
n
ar
d
 e
t 
al
., 
19
97
) 
α
2-
m
ac
ro
g
lo
b
u
li
n
, 
h
ep
at
o
g
lo
b
u
li
n
, 
li
p
o
p
ro
te
in
 A
1,
 
b
il
ir
u
b
in
 a
n
d
 δ
-
g
lu
b
u
li
n
. 
H
C
V
 
80
 
t 
=
0.
84
, v
 =
87
 
75
 
85
 
>
90
/
10
0 
www.intechopen.com
 
Reversal of Liver Fibrosis: A Review 
 
69 
al., 2002).  FT-AT provides an accurate measurement of bridging fibrosis and/or moderate 
necroinflammatory activity with the area under the receiver operating curve (AUROC) 
predictive value, between 0.70 and 0.80, when compared to liver biopsy (Sporea et al., 
2008) (Table 1 summarized the diagnostic performance of noninvasive tests of liver 
fibrosis). 
6. Limitations of serum biomarkers 
One limitation of biomarkers is that none is liver-specific and they may be influenced by 
changes in their clearance and excretion. The inter-laboratory reproducibility of scores such 
as FibroTest has been shown to be satisfactory for use in clinical practice (Cales et al., 2008).  
Careful interpretation of each test is required e.g., when using FibroTest, the existence of 
haemolysis or Gilbert syndrome can lead to false-positive results (by a decrease haptoglobin 
or an increase in bilirubin, respectively)(Castera et al., 2011). 
7. Imaging methods 
Imaging techniques are an attractive way of evaluating fibrosis because they are 
noninvasive and have the ability to detect structural changes, which serological-based tests 
of fibrosis and inflammation are unable to do. Using the modalities of ultrasound, computed 
tomography or magnetic resonance imaging (MRI), it is possible to diagnose features of 
advanced chronic liver disease by recognizing surrogate markers of portal hypertension 
(e.g. splenomegaly, ascites..etc) with a high degree of sensitivity and specificity. However, 
these techniques do not reliably detect lesser degrees of fibrosis. Even diagnosis of cirrhosis 
is often based only on signs of advanced liver cirrhosis, e.g., signs of portal hypertension, a 
shrunken right liver lobe with enlargement of the caudate lobe, resulting in a high 
specificity but lower sensitivity of the methods (Honda et al., 1990). Ultrasound studies 
combining several ultrasound parameters and Doppler measurements achieved accuracies 
for the diagnosis of cirrhosis up to a maximum of 88% (Aubé et al., 1999).  Commonly used 
imaging methods are discussed in the next section. 
7.1 Transient elastography or fibroscan 
Transient elastography (TE), or FibroScan (Echosens, Paris, France), is a novel technology 
for measuring liver stiffness (Ziol et al., 2005).  The scan was developed on the principle that 
livers with increasing degrees of scarring or fibrosis have decreasing elasticity and that a 
shear wave propagating through stiffer material would progress faster than in a more elastic 
material. Thus, the stiffer the liver, the faster the sheer waves propagate. The ultrasound 
transducer probe is mounted on the axis of a vibrator. Pulse-echo ultrasound waves then 
measure the velocity of the shear wave in the liver tissue at a distance of 2.5–6.5 cm under 
the skin level, which corresponds to a measured distance of 4 cm in the liver tissue. TE is 
rapid (less than 5 minutes), highly reproducible and can easily be performed bedside or in 
the outpatient clinic with immediate results. Liver stiffness corresponds to the median value 
of ten validated measurements that range from 2.5 to 75 kPa, with normal values around 5.5 
kPa (Castera et al., 2008).  
TE provides clinicians with a noninvasive, accurate, and reproducible tool to estimate liver 
fibrosis. Numerous studies have shown that this technique is an excellent tool for the 
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detection of advanced fibrosis or cirrhosis, but the results for the prediction of different 
stages of moderate fibrosis are less conclusive. Due to its noninvasive nature, simple 
training and ease of use, TE can be used repeatedly on patients and is optimal for large-scale 
studies, in which healthy patients with no indication for liver biopsy can also be included. 
This technique has the advantage of being safe, reproducible, and rapid. However, falsely 
high liver stiffness measurements might also occur during acute hepatitis, extrahepatic 
cholestasis, congestive heart failure, and amyloidosis (Castera et al., 2010). Failed acquisition 
was commonly due to obesity, particularly increased waist circumference, and limited 
operator experience. However, development of S and XL probes might overcome this 
limitation. A meta-analysis of nine studies (Talwalkar et al., 2007) showed that TE has a 
sensitivity of 87% (95% CI 84%–90%) and a specificity of 91% (95% CI 89%–92%) for 
diagnosing cirrhosis. In seven of the nine studies, Stage 2 to 4 fibrosis was diagnosed with 
70% sensitivity (95% CI 67%–73%) and 84% specificity (95% CI 80%–88%). Foucher et al. 
reported that, in 144 chronic hepatitis C patients with fibrosis at stage 3 or 4, the cut-off 
values of liver stiffness measured by TE were 27.5, 49.1, 53.7 and 62.7 kPa for the appearance 
of esophageal varices (Stage 2/3), ascites, HCC and rupture of esophageal varices (Castéra 
et al., 2010).  
7.2 Magnetic resonance elastography 
Few studies that focus on MRI detection and quantification of liver fibrosis currently exist. 
More recently, a liver stiffness evaluation (LSE) by MR elastography (MRE) has been 
demonstrated to provide high accuracy for the noninvasive diagnosis of liver fibrosis 
(Talwalkar et al., 2008; Huwart et al., 2008).  The technique used is similar to that used in 
ultrasound elastography in that it uses a vibration device to induce a shear wave in the liver. 
Liver elasticity is evaluated using an external probe at the back of the patient and sending 
low frequency vibrations (60 Hz) through the liver and measuring the MRI spin-echo 
sequence. With this technique, shear elasticity and viscosity maps are obtained, and a color-
coded image is generated that depicts the wave velocity, and thus the stiffness, throughout 
the organ. A study comparing the MRE of thirty healthy volunteers and fifty patients with 
chronic liver disease with liver histology showed a sensitivity of 86% and a specificity of 
85% for discrimination between patients with moderate and severe fibrosis (Metavir F2–F4) 
and those with mild fibrosis (Yin et al., 2007).  However, MRE is expensive, and cost may 
limit its use. Thus, it may not be readily available at all hospitals.    
7.3 Acoustic radiation force impulse 
Acoustic radiation force impulse (ARFI) is a new technology for LSE which uses an add-on 
module to the standard ultrasound imaging device. It involves targeting an anatomic region 
for interrogation of the elastic properties with the use of a region of interest cursor while 
performing real-time B-mode imaging. An initial ultrasonic pulse is transmitted at 
diagnostic intensity levels to obtain a baseline signal for later comparison. A short-duration 
(approximately 0.3 s), high-intensity acoustic ‘pushing pulse’ is then transmitted by the 
same transducer and is followed by a series of diagnostic intensity pulses, which are used to 
track the displacement of the tissue caused by the pushing pulse (Palmeri et al., 2005).  By 
measuring the time-to-peak displacement at each lateral location, one can reproduce the 
shear-wave speed of the tissue. The shear-wave propagation velocity is proportional to the 
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square root of tissue elasticity. Results are expressed in meters per second (m/s) (range, 0.5–
4.4 m/sec; ±20% accuracy over the range). In a study performed by Friedrich-Rust et al., 
2009; ARFI was compared to LB and blood markers of liver fibrosis in 86 patients with 
chronic hepatitis (B or C). The Spearman correlation coefficients between the histological 
fibrosis stage and ARFI, TE, FibroTest and APRI scores indicated significant correlations: 
0.71, 0.73, 0.66 and 0.45, respectively (p<0.001). 
Newer imaging estimation of hepatic fibrosis appears promising. TE & ARFI appear to be 
excellent tools for early detection of cirrhosis with likely prognostic value in this setting. 
8. Combination of serum markers and imaging methods 
The use of sequential or combined serum tests and imaging to provide better prediction for 
significant fibrosis (METAVIR stages F2–F4) or cirrhosis, and thus a reduction in the need 
for biopsy in patients with chronic hepatitis C (CHC), is gaining support. Certainly, the 
stepwise concept of using a highly sensitive test to first rule out significant disease and then 
using a more specific test to confirm the diagnosis if the test results are positive is 
advantageous. One recent approach integrated a biopsy into a clinical decision algorithm by 
targeting patients with indeterminate or misclassified values with marker panels. The 
Sequential Algorithms for Fibrosis Evaluation (SAFE) biopsy study (Sebastiani et al., 2009) 
evaluated the APRI followed by FT-AT in 2035 CHC patients from nine clinical centers in 
the United States and Europe. Using this sequential approach, the number of biopsies saved 
at baseline was 47 and 82% with an overall accuracy of 90% for Stages F2–F4 and cirrhosis, 
respectively. Another study (Paggi et al., 2008) noted that the combination of APRI and a 
simple ultrasound assessment of the presence of liver surface nodularity could predict 
stages F3–F4 in 54% of CHC patients.  
These techniques certainly appear to be valid approaches for reducing the need for biopsy in 
CHC patients. The combined use of TE and biochemical markers seems to be the most 
promising noninvasive techniques which can help the clinician decide whether a liver 
biopsy is necessary in some patients, and accordingly decide who to treat. 
9. Conclusions 
Our understanding of the mechanism of liver fibrosis has changed dramatically over the last 
decade and is no longer viewed as permanent but rather as a dynamic process. The HSC 
play a critical role in fibrogenesis. Reversal of fibrosis is accompanied by clearance of HSC 
and treatment of the primary cause of injury can allow complete resolution of fibrosis. Liver 
biopsy is the current reference test for the assessment of hepatic fibrosis, but because of its 
limitations, noninvasive markers of liver fibrosis have been developed. Although none of 
the currently available noninvasive marker of fibrosis are an ideal test to accurately 
differentiate between disease stages, the combination of serum markers, and imaging 
appear to have good predictive values in excluding patients with cirrhosis. 
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